Brilinta (TM) - ticagrelor, AstraZeneca's new heart drug - Biotech, Pharma and Life Science Channel

09:23 EST 12th December 2017 | BioPortfolio


Brilinta - ticagrelor, AstraZeneca's new heart drug is a blood-thinning medicine designed to prevent dangerous blood clots in patients with serious chest pain or previous heart attacks. It reduces the clumping of blood particles, called platelets, that promote clotting.

Analysts believe that peak sales of Brilinta could reach $2bn or more, but Brilinta will face stiff competition in the blood-thinning market, notably from Plavix.


BRILINTA is a type of prescription antiplatelet medication for people who have had a recent heart attack or severe chest pain that happened because their heart wasn't getting enough oxygen and who are being treated with medicines or procedures to open blocked arteries in the heart. BRILINTA is used with aspirin to stop platelets from sticking together and forming a blood clot that could block blood flow to the heart and cause another, possibly fatal, heart attack. Platelets are small cells in the blood that help with normal blood clotting.


BRILINTA used with aspirin lowers your chance of having another serious problem with your heart or blood vessels such as heart attack, stroke, or blood clots in your stent if you received one. These can be fatal. In fact, in a large clinical study BRILINTA was even better than Plavix® (clopidogrel bisulfate) tablets at lowering your chances of having another heart attack.

Key documents: Patient Prescribing Information ~ Medication Guide

BRILINTA is a trademark of the AstraZeneca group of companies.

Plavix® is a registered trademark of sanofi-aventis.

News Articles [5 Associated News Articles listed on BioPortfolio]

Celebrity Trainer and Author Bob Harper Teams up with AstraZeneca to Connect with Fellow Heart Attack Survivors

Survivors Have Heart Essay Contest calls on heart attack survivors to submit their stories for the opportunity to educate and inspire other survivors at an event hosted by Bob Har...

PhaseBio Enters Worldwide License Agreement with MedImmune for a Reversal Agent for Ticagrelor

First-in-class and unique reversal agent for ticagrelor aims to address important unmet need for patients requiring antiplatelet therapyPotential for accelerated development timeline with Phase 1 i...

AstraZeneca Shares Scientific Updates from Its Extensive Cardiovascular, Renal and Metabolic Diseases (CVMD) Portfolio at AHA 2017

AstraZeneca and MedImmune, its global biologics research and development arm, will be underlining its scientific focus on cardiovascular, renal and metabolic diseases (CVMD) with ...

SMS Pharmaceuticals Ltd SMSPHARMA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 11102017] Prices from USD $250

SummarySMS Pharmaceuticals Ltd SMS Pharma is a manufacturer of active pharmaceutical ingredients APIs and intermediates that develops offers antifungal, antiulcer, antimigraine, antihypersensitive, an...

Kopran Ltd KOPRAN Financial and Strategic SWOT Analysis Review [Report Updated: 07082017] Prices from USD $300

SummaryKopran Ltd Kopran is a pharmaceutical company that provides finished dosage forms, consumer healthcare products and active pharmaceutical ingredients. The company's finished dosage form product...

Events [0 Results]


Companies [0 Results]


Clinical Trials [120 Associated Clinical Trials listed on BioPortfolio]

Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome

H-REPLACE trial is a prospective, randomized, open-label, active-controlled, multicenter study in participants with ACS (STEMI or NSTEMI, unstable angina). All eligible participants receiv...

TicagRelor Or Clopidogrel in Severe and Terminal Chronic Kidney Disease Patients Undergoing PERcutaneous Coronary Intervention for an Acute Coronary Syndrome.

Ticagrelor is a potent and fast-acting P2Y12-ADP receptor antagonist recommended as first-line agent in ACS (2). This drug was associated with a 20% relative reduction in the rate of MACE ...

THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death

Study to investigate if the study drug ticagrelor and ASA is more effective than Placebo (inactive tablet) and ASA in preventing new stroke events.

Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes

The antiplatelet agent clopidogrel is an effective drug for the prevention of thrombotic events in patients with acute coronary syndromes, and is therefore one of the most frequently presc...

OFDI-Quantified Intracoronary Thrombus, Antiplatelet Pretreatment Effect and Myocardial Reperfusion

The management of ST-elevation myocardial infarction in the acute phase requires an optimal antiaggregation combining aspirin and a P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor). ...

Safety and Efficacy of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Angioplasty

Currently, there is a minimal data on the combination of rivaroxaban and ticagrelor in patients with atrial fibrillation (AF) managed with percutaneous coronary intervention (PCI). Further...

Effect of Haemodialysis on the Efficacy of Antiplatelet Agents

The main purpose of our study is to investigate whether haemodialysis itself affects the efficacy of antiplatelet drugs and the effects of two different types of dialysis membranes (polysu...

Effectiveness of Lower Maintenance Dose of Ticagrelor Early After Myocardial Infarction (ELECTRA) Pilot Study

The ELECTRA pilot study is a randomized, open-label, pharmacokinetic and pharmacodynamic trial designed to evaluate the effect of ticagrelor maintenance dose reduction on platelet inhibiti...

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI

In STEMI patients undergoing PPCI there is a delayed onset of action of oral P2Y12 receptor inhibitors, including prasugrel and ticagrelor. Crushing prasugrel and ticagrelor improves their...

Comparison Of Efficacy and Safety Between Ticagrelor and Clopidogrel In Chinese

This is a prospective, single-center study to assess the long- and short-term outcomes of ticagrelor vs clopidogrel in Chinese patients with acute coronary syndrome undergoing percutaneous...

PubMed Articles [40 Associated PubMed Articles listed on BioPortfolio]

The use of alternatives to clopidogrel in flow-diversion treatment with the Pipeline embolization device.

OBJECTIVE Thromboembolic complications continue to be encountered with Pipeline embolization devices (PEDs) despite routine clopidogrel/aspirin antiplatelet therapy. This study examined the safety and...

One-Year Clinical Effectiveness Comparison of Prasugrel with Ticagrelor: Results from a Retrospective Observational Study using an Integrated Claims Database.

No direct comparisons of ticagrelor and prasugrel with 1-year clinical follow-up have been reported.

Is ticagrelor safe in intensive care unit patients? Focus on bradycardic events.

Decreased platelet inhibition by P2Y12 receptor blockers in anemia.

Anemic patients undergoing angioplasty and stenting are at an increased risk of ischemic events, which may be caused by an inadequate response to antiplatelet therapy with adenosine diphosphate (ADP) ...

Antithrombotic treatment in peripheral artery disease.

This review treats antithrombotic use for peripheral arterial disease (PAD). In asymptomatic patients, there are no scientific data to support single antiplatelet therapy (SAPT) for primary prophylaxi...

Clinical effectiveness and safety of ticagrelor in patients after PCI because of acute non ST segment elevation myocardial infarction.

Objective: To observe the clinical effectiveness and safety of ticagrelor in patients after percutaneous coronary intervention (PCI) because of acute non ST segment elevation myocardial infarction (NS...

Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events.

Ticagrelor (Brilique(®)) is an orally administered P2Y12 inhibitor. A long-term (maintenance) regimen of ticagrelor 60 mg twice daily is indicated in the EU for coadministration with low-dose aspiri...

Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease.

Patients with type 2 diabetes mellitus (T2DM) are at higher risk of thrombotic complications. Studies have indicated that patients with T2DM have impaired clopidogrel-induced antiplatelet effect. Tica...

Effect of ticagrelor versus prasugrel on platelet reactivity: a meta-analysis.

Whether ticagrelor is superior to prasugrel in inhibiting platelet reactivity (PR) has remained unclear, possibly because different test methods have been used to determine this. Therefore, using a di...

Is Ticagrelor Safe in Octogenarian Patients with Non-ST Elevation Acute Coronary Syndromes?


None available.

Medical and Biotech [MESH] Definitions

None available.

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

review and buy Brilinta (TM) - ticagrelor, AstraZeneca's new heart drug market research data and corporate reports here

Channels Quicklinks